Autres langues Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Actions

TEVA

IL0006290147

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 13:24:08 25/04/2024			Varia. 5j.	Varia. 1 janv.
4 933 ^ILa	+0,98 %		-0,90 %	+29,31 %

17/04	Alvotech et Teva annoncent l'approbation par la FDA américaine de SELARSDI (ustekinumab-aekn), biosimilaire de Stelara (ustekinumab)	CI
11/04	L'unité pharmaceutique de Teva déclare que l'essai de stade avancé en Chine de l'Ajovy pour la prévention de la migraine a atteint les objectifs primaires et secondaires	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	22/04
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	17/04
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17/04
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	16/04
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16/04
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16/04
Teva Pharmaceutical Industries : Immediate Report	16/04
Teva Pharmaceutical Industries : Immediate Report	16/04
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment	16/04
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets	16/04
Teva enters into oncology biosimilar licensing agreement	16/04
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	11/04
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China	11/04
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China	11/04
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024	09/04
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY Extended-Release Injectable Suspension at SIRS 2024	08/04
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024	06/04
TEVA Successfully Opposed Trademark AZILIDE	05/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Teva Pharmaceutical Industries Limited : Doit encore lâcher du lest

Le 01 février 2024 à 10:03

INTERVIEW - Richard Francis, PDG de Teva Pharmaceutical : trimestre solide, prévisions annuelles relevées

Le 02 août 2023 à 21:19